Zealand Pharma A/S (OTCMKTS:ZLDPF) Stock Price Down 10.3% – Here’s Why

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s share price dropped 10.3% during mid-day trading on Monday . The stock traded as low as $48.45 and last traded at $48.45. Approximately 200 shares changed hands during mid-day trading, a decline of 95% from the average daily volume of 3,780 shares. The stock had previously closed at $54.00.

Analysts Set New Price Targets

A number of analysts have weighed in on ZLDPF shares. William Blair reissued a “market perform” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Finally, BNP Paribas Exane downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. Three research analysts have rated the stock with a Strong Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, Zealand Pharma A/S presently has a consensus rating of “Moderate Buy”.

Zealand Pharma A/S Trading Down 1.6%

The firm has a market cap of $3.44 billion, a price-to-earnings ratio of 3.57 and a beta of 0.87. The firm’s 50-day moving average is $45.92 and its 200-day moving average is $62.02. The company has a current ratio of 23.57, a quick ratio of 23.57 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its earnings results on Thursday, May 7th. The company reported ($0.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.50. The company had revenue of $5.33 million for the quarter, compared to analyst estimates of $2.81 million. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.50%. As a group, sell-side analysts anticipate that Zealand Pharma A/S will post 2.95 EPS for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.